FDA NDC Directory · JSON-LD · Markdown

JAKAFI

NDC 50881-025 · HUMAN PRESCRIPTION DRUG · TABLET

Generic nameruxolitinib
Labeler / ManufacturerIncyte Corporation
Marketing categoryNew Drug Application (innovator) · App NDA202192
Dosage form / routeTABLET · ORAL
Active ingredientsRUXOLITINIB (25 mg/1)
Marketing started20111116
Package count1

External sources

Source: openFDA. Public-domain (CC0).